• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • BioMed Audio Podcast Library @LPBI Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses

Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses

Curator: Aviva Lev-Ari, PhD, RN

Part One: 

Anti-Cancer MATERIALS TO BE REVIEWED by Scientist Candidates for the Anti-Cancer Indication

Part Two: 

2.0   Immune System Stimulants

2.1   New Class of Immune System Stimulants: Cyclic Di-Nucleotides (CDN), UC, Berkeley

2.2  Basic Research in Immune Oncology and Molecular Genomics: Methods to Stimulate Immunity by Alteration of Tumor Antigens, MGH

2.3   T Cells Receptor Like (TCRL) Antibodies – Technion, Israel

Part Three: 

Anti-Cancer – Four Drug Classes of Immune-Oncology Molecules in Development, including CAR-T

 

Part One: 

Anti-Cancer MATERIALS TO BE REVIEWED by Scientist Candidates for the

Anti-Cancer Indication

 

  • Potential involvement in Drug Discovery on Anti-Cancer – CAR–T and TCRL in a newly under formation Biotech Start up as Scientist I,II,III or Project R&D Management

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/anti-cancer-car-t/

 

Start up will have employment opportunity for Scientist I,II,III and Project R&D Management positions per experience pending Funding secured to finance the Drug Discovery projects for the Three Indication, as above

Anti-Cancer MATERIALS TO BE REVIEWED by Scientist Candidates

For the Anti-Cancer Indication – Scientist Candidates will review the following links:

 

  • Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • Series C: e-Books on Cancer & Oncology

Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

  • Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed

Reporter: Aviva Lev-Ari, PhD, RN

  • Pull at Cancer’s Levers 

Curator: Larry H. Bernstein, MD, FCAP

  • Dr. David Orange-Webb Presentation to LPBI Group’s Team – April 8, 2016

    https://docs.google.com/presentation/d/1AKyBcHWlWdVE1JEVJn27XXpHCnXBKndzPZ6o6fJz5Mk/edit?pref=2&pli=1#slide=id.g10f889dcef_2_99

  • Oncolytic Viruses in Cancer Therapy @ CHI’s PreClinical Congress, June 14, 2016 Westin Boston Waterfront, Boston

Reporter: Aviva Lev-Ari, PhD, RN

  • Oncolytic Virus Immuno-Therapy: New Approach for a New Class of Immunotherapy Drugs

Curator: Larry H. Bernstein, MD, FCAP

  • Real Time Coverage and eProceedings of 2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

Curator of Reported Contents: Aviva Lev-Ari, PhD, RN

  • Pancreatic Cancer: Articles of Note @PharmaceuticalIntelligence.com

Part Two

2.0 Immune System Stimulants

  • Immune System Stimulants: Articles of Note @pharmaceuticalintelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

  • Immune System in Perspective

Curator: Larry H. Bernstein, MD, FCAP

  • Three Methods for Design of a Novel Immune Therapy for Cancer: Conceptual Foundation for Development of a Novel Mechanism of Action for a Combination Therapy of Biologics

Curator:  Aviva Lev-Ari, PhD, RN

  • Issues Need to be Resolved With Immuno-Modulatory Therapies: NK cells, mAbs, and adoptive T cells

Curator: Stephen J. Williams, PhD

  • Cancer Research Institute, NYC, 6/23 – 6/24/2016: Will combination of adoptive t-cell therapy and anti-checkpoint inhibitor therapies be the next wave?

Reporter: Aviva Lev-Ari, PhD, RN

  • From the Walter and Eliza Hall Institute of Medical Research: Hobbit and Blimp1 May Be Needed for Local Tissue Immune Response

Reporter: Stephen J Williams, PhD

  • Targeting KRAS Mutations In Pancreatic Tumours

Curator: David Orchard-Webb, PhD

  • Progress in the Design, Testing, and Approval of Immuno-therapeutic Reagents: Target the Most Promising Cancer Antigens  – NCI Pilot Project for the Acceleration of Translational Research

Reporter: Aviva Lev-Ari, PhD, RN

  • The Value of Prediction for Response to Immunotherapies: Genomic Approaches for the Advancement of Neo-Antigen Understanding in Immunotherapy

Reporter: Aviva Lev-Ari, PhD, RN

 

2.1   New Class of Immune System Stimulants: Cyclic Di-Nucleotides (CDN), UC, Berkeley

 

  • New Class of Immune System Stimulants: Cyclic Di-Nucleotides (CDN): Shrink Tumors and bolster Vaccines, re-arm the Immune System’s Natural Killer Cells, which attack Cancer Cells and Virus-infected Cells

Reporter: Aviva Lev-Ari, PhD, RN

  • Adoptive NK T-Cells in Cancer Therapy

Curator: Larry H. Bernstein, MD, FCAP

  • Novel molecules VY-OZ and VY-X demonstrate enhancement of killing capacity for cytotoxic lymphocytes by T-cells and natural killer cells (NK-cells) – products delivering: gene modification increasing in vivo and ex vivo immune response @Vycellix, Sarasota, FL

Reporter: Aviva Lev-Ari, PhD, RN

  • CD-4 Therapy for Solid Tumors

Curator: Larry H. Bernstein, MD, FCAP

 

2.2  Basic Research in Immune Oncology and Molecular Genomics: Methods to Stimulate Immunity by Alteration of Tumor Antigens, MGH

  • Basic Research in Immune Oncology and Molecular Genomics: Methods to Stimulate Immunity by Alteration of Tumor Antigens

Reporter: Aviva Lev-Ari, PhD, RN

 

  • http://cancerres.aacrjournals.org/content/74/19_Supplement/2893.abstract

 

  • http://conference.ncri.org.uk/abstracts/2013/abstracts/B63.htm

2.3   T Cells Receptor Like (TCRL) Antibodies: Major Considerations, Technion, Israel

  1. Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase.

Co-localization experiments revealed that, in cell lines presenting low levels of HLA-A2-Tyr ((369-377)) complexes, tyrosinase co-localizes with LAMP-1, a melanosome marker, whereas in cell lines presenting high HLA-A2-Tyr((369-377)) levels, tyrosinase localizes to the endoplasmic reticulum. We also observed differences in tyrosinase molecular weight and glycosylation composition as well as major differences in protein stability (t(1/2) ). By stabilizing the tyrosinase protein, we observed a dramatic decrease in HLA-A2-tyrosinase presentation.

Eur J Immunol. 2012 Apr; 42(4):842-50.    http://dx.doi.org:/10.1002/eji.201141511

 

  1. Tumour and virus-infected cells are recognised by CD8+ cytotoxic T cells that, in response, are activated to eliminate these cells.

In order to be activated, the clonotypic T-cell receptor (TCR) needs to encounter a specific peptide antigen presented by the membrane surface major histocompatibility complex (MHC) molecule. Cells that have undergone malignant transformation or viral infection present peptides derived from tumour-associated antigens or viral proteins on their MHC class I molecules. Therefore, disease-specific MHC-peptide complexes are desirable targets for immunotherapeutic approaches. One such approach transforms the unique fine specificity but low intrinsic affinity of TCRs to MHC-peptide complexes into high-affinity soluble antibody molecules endowed with a TCR-like specificity towards tumour or viral epitopes. These antibodies, termed TCR-like antibodies, are being developed as a new class of immunotherapeutics that can target tumour and virus-infected cells and mediate their specific killing. In addition to their therapeutic capabilities, TCR-like antibodies are being developed as diagnostic reagents for cancer and infectious diseases, and serve as valuable research tools for studying MHC class I antigen presentation.
Expert Rev Mol Med. 2012 Feb 24; 14:e6.    http://dx.doi.org:/10.1017/erm.2012.2

 

  1. we propose and demonstrate a generic electrical-to-biological transducer comprising a two-state electronic antigen and a chimeric cell receptor engineered to bind the antigen exclusively in its “on” state. T-cells expressing these receptors remain inactivated with the antigen in its “off” state. Switching the antigen to its “on” state by an electrical signal leads to its recognition by the T-cells and correspondingly to cell activation.

Nano Lett. 2011 Nov 9; 11(11):4997-5001. http://dx.doi.org:/10.1021/nl202971r

 

  1. antigen targeting via the human DCIR receptor allows activation of specific CD8(+) T-cell immunityEnhanced specific CD8(+) T-cell responses were observed when an antigen was delivered to the DCs via DCIR, compared with those induced by a free antigen, or antigen conjugated to a control monoclonal antibody or delivered via DC-SIGN, another lectin receptor. DCIR targeting also induced primary CD8(+) T-cell responses against self (MART-1) and viral (HIV gag) antigens. Addition of Toll-like receptor (TLR) 7/8 agonist enhanced DCIR-mediated cross-presentation as well as cross-priming2010 Sep 9; 116(10):1685-97.  http://dx.doi.org:/10.1182/blood-2010-01-264960

 

  1. unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.

J Immunol. 2009 May 15; 182(10):6328-41.    http://dx.doi.org:/10.4049/jimmunol.0801898

 

  1. Heterogeneous cell populations form an interconnected network that determine their collective output

Despite the large number of subpopulations compositions, we were able to computationally extract a simple set of subpopulation-based rules that accurately predict the degree of reactivity. This raised the conjecture of whether one could control reactivity of TILs by manipulating their subpopulation composition. Remarkably, by rationally enriching and depleting selected subsets of subpopulations, we were able to restore anti-tumor reactivity to nonreactive TILs

Mol Syst Biol. 2009; 5:265.    http://dx.doi.org:/10.1038/msb.2009.15

 

  1. the human skin displays three DC subsets, two of which, i.e., CD14(+) DCs and LCs, display functional specializations, the preferential activation of humoral and cellular immunity

Immunity. 2008 Sep 19; 29(3):497-510.    http://dx.doi.org:10.1016/j.immuni.2008.07.013

 

  1. many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents;

This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations.         Oncogene. 2007 May 28;26(25):3714-33.

 

9. Dr. David Orchard-Webb Presentation to LPBI Group’s Team – April 8, 2016

  • https://docs.google.com/presentation/d/1AKyBcHWlWdVE1JEVJn27XXpHCnXBKndzPZ6o6fJz5Mk/edit?pref=2&pli=1#slide=id.g10f889dcef_2_99

Part Three

Anti-Cancer – Four Drug Classes of Immune-Oncology

Molecules in Development, including CAR-T

 

Curator: Stephen J Williams, PhD

Phase in
Development
Checkpoint Inhibitors
Drug/Pharma
 
 Co-Stimulatory Agents
Drug/Pharma
 Immunomodulators
Drug/Pharma
5th generation CAR Signaling
Pharma/Partners
Listed as
Drug (Target/disease indication)
Pre-Clinical
 REGN2810/Regeneron
PD-1/Agenus
Anti-Lag3/Tesaro, AnaptyBio
IMP701/Prima BioMed
LAG3/Agenus, Incyte
Lag3/Merck
Anti-TIM3/Bristol
Anti-TIM3/Tesaro, AnaptyBio
Anti-TIM3/Agenus
 OX40/Amgen
GITR/Bristol
GITR/Pfizer
FPA154/Five Prime
Anti-GITR/TG Therapeutics
Anti-GITR/Incyte
CTLA4/Agenus
IDO1/Pfizer,iTEOS
F001287/Bristol,Flexus
IMA942/Roche
VIBR/Pfizer
 Kite Pharma/Amgen
Multiple targets/ hematologic & solid tumors
Bellicum Pharma
BPX-401 (CD19/leukemia)
BPX-601 (PSCA/prostate)
BPX-701 (PRAME/melanoma
Cellectis/PfizerCornel/Ohio State
UCART123 (CD123/AML)
UCARTCS1 (CD38/multiple myeloma)
UCART 38 (CD38 /multiple myeloma)
UCART 22 ( CD22/ALL)
Juno Therapeutics/Cellgene
MUC116 (IL12/ovarian)
ROR1 (ROR1/B-ALL)
Univ. of Penna/Novartis
CAR-T hPSMA (PSMA/prostate)
Phase I
 BMS986016/Bristol
Urelumab/ BristolMyers
MEDI-0562/ AstraZeneca
RG7888/Roche
OX40/Agonox
OX40/GSK
MK-4166/Merck
SEA-CD40/Seattle Genetics
CD40/Roche
 Anti-CEA Il2v/Roche
FPA008/Bristol, Five Prime
LY3022855/Lilly
AMG820/Amgen
ARRY382/Array, Celgene
 Ziopharm/Intrexon/ MD Anderson
CD19 (CD19/B-ALL)
Kite Pharma/Amgen
KTE-C19 (ZUMA-3/Adult ALL)
KTE-C19 (ZUMA-4/pediatric ALL)
EGFRvII (EGFR/glioblastoma)
Bluebird Bio/Cellgene/Baylor
bb2121 (BCMA/B-ALL)
Juno Therapeutics/Cellgene
JCAR017 (CD19/leukemias)
JCAR014 (CD19/NHLymphoma)
Phase I/II
 MEDI0680/AstraZenec
PF-05082566/Pfizer
Varilumab/Celldex, Bristol-Myers
 NKG2A/Innate,AstraZen.
dCellVax/BioMatrix
APN301/Apeiron, MerckKGA
 Juno Therapeutics/Cellgene
JCAR015 (CD19/ALL)
JTCR016 (WT-1/AML,CML)
Phase II
 Pidlizumab/Medivation
Avelumab/Pfizer, MerckKGa
Lirilumab/BMY/Innate
Epacadostat/Incyte, Merck
GDC-0919/NewLinkGenetics, Roche
TG4010/Transgene S.A.
Ontak/Esai, Lilly, Teva
Denenicokin/Bristol, NovoNordisk
PLX3397/Plexikon, Merck
MCS110/Novartis
JNJ40346527/JNJ
T-Vec/Amgen
Emactuzumab/Roche
 Univ. of Penna/Novartis
CTL019 (CD19/leukemia)
Kite Pharma/Amgen
KTE-C19 (ZUMA-1/leukemia)
KTE-C19 (ZUMA-2/mantle cell leukemia)
Phase III
 Duvalumab/AstraZenca
Atezolizumab/Roche
Tremelimumab/AstraZeneca
Approved
 Opdivo/Bristol-Myers
Keytruda/Merck
Yervoy/Bristol-Myers

 Please see the following table In Word (as an 11 x 17 format table) below:

Table JPM2016 ImmuneTherapy in Development

 

 

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,319 other subscribers
  • Recent Posts

    • The Current Impact and Future of Technology within Cardiovascular Surgery September 23, 2023
    • The Continued Impact and Possibilities of AI in Medical and Pharmaceutical Industry Practices September 18, 2023
    • Regulatory T cells (Tregs) are important for sperm tolerance and male fertility September 11, 2023
    • ChatGPT Chemistry Assistant for Text Mining and the Prediction of metal–organic framework (MOF) synthesis August 27, 2023
    • Eight Subcellular Pathologies driving Chronic Metabolic Diseases – Methods for Mapping Bioelectronic Adjustable Measurements as potential new Therapeutics: Impact on Pharmaceuticals in Use August 19, 2023
    • ChatGPT Searches and Advent of Meta Threads: What it Means for Social Media and Science 3.0 July 11, 2023
    • OpenAI and ChatGPT face unique legal challenges over CopyRight Laws July 10, 2023
    • World Medical Innovation Forum, June 12 – June 14, 2023 The Westin Boston Seaport District organized by Mass General Brigham (MGB) June 25, 2023
    • Revolutionizing Business with Apple Vision Pro: The Ultimate Tool for Enhanced Visual Communication June 22, 2023
    • Optimism for Future Equality of Access to Healthcare in the Inaugural address as AMA President, Jesse M. Ehrenfeld, MD, MPH | AMA 2023 Annual Meeting of House of Delegates June 14, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aptubman
    • 1 Arav Gandhi
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 FrasonKalapurackal
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: